Log in

NASDAQ:EKSOEkso Bionics Competitors & Alternatives

$7.35
+0.12 (+1.66 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.16
Now: $7.35
$7.94
50-Day Range
$3.00
MA: $4.43
$8.77
52-Week Range
$2.25
Now: $7.35
$19.65
Volume1.09 million shs
Average Volume8.97 million shs
Market Capitalization$55.79 million
P/E RatioN/A
Dividend YieldN/A
Beta2.06

Competitors

Ekso Bionics (NASDAQ:EKSO) Vs. PSTI, PRTK, IVC, FBIO, JNCE, and LQDA

Should you be buying EKSO stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Ekso Bionics, including Pluristem Therapeutics (PSTI), Paratek Pharmaceuticals (PRTK), Invacare (IVC), Fortress Biotech (FBIO), Jounce Therapeutics (JNCE), and Liquidia Technologies (LQDA).

Ekso Bionics (NASDAQ:EKSO) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Ekso Bionics and Pluristem Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ekso Bionics-68.97%-210.43%-59.23%
Pluristem TherapeuticsN/A-152.78%-101.67%

Earnings and Valuation

This table compares Ekso Bionics and Pluristem Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ekso Bionics$13.92 million4.01$-12,130,000.00($3.45)-2.13
Pluristem Therapeutics$50,000.004,443.94$-35,310,000.00N/AN/A

Ekso Bionics has higher revenue and earnings than Pluristem Therapeutics.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Ekso Bionics and Pluristem Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ekso Bionics00303.00
Pluristem Therapeutics00503.00

Ekso Bionics currently has a consensus target price of $11.00, suggesting a potential upside of 49.66%. Pluristem Therapeutics has a consensus target price of $12.8750, suggesting a potential upside of 44.34%. Given Ekso Bionics' higher possible upside, equities analysts plainly believe Ekso Bionics is more favorable than Pluristem Therapeutics.

Insider & Institutional Ownership

23.5% of Ekso Bionics shares are held by institutional investors. Comparatively, 7.8% of Pluristem Therapeutics shares are held by institutional investors. 24.3% of Ekso Bionics shares are held by insiders. Comparatively, 4.9% of Pluristem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Ekso Bionics has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, Pluristem Therapeutics has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500.

Summary

Ekso Bionics beats Pluristem Therapeutics on 6 of the 11 factors compared between the two stocks.

Paratek Pharmaceuticals (NASDAQ:PRTK) and Ekso Bionics (NASDAQ:EKSO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Earnings and Valuation

This table compares Paratek Pharmaceuticals and Ekso Bionics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Paratek Pharmaceuticals$16.54 million13.43$-128,790,000.00($3.93)-1.31
Ekso Bionics$13.92 million4.01$-12,130,000.00($3.45)-2.13

Ekso Bionics has lower revenue, but higher earnings than Paratek Pharmaceuticals. Ekso Bionics is trading at a lower price-to-earnings ratio than Paratek Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Paratek Pharmaceuticals has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Ekso Bionics has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500.

Profitability

This table compares Paratek Pharmaceuticals and Ekso Bionics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Paratek Pharmaceuticals-528.28%N/A-47.65%
Ekso Bionics-68.97%-210.43%-59.23%

Insider and Institutional Ownership

43.4% of Paratek Pharmaceuticals shares are held by institutional investors. Comparatively, 23.5% of Ekso Bionics shares are held by institutional investors. 7.7% of Paratek Pharmaceuticals shares are held by company insiders. Comparatively, 24.3% of Ekso Bionics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Paratek Pharmaceuticals and Ekso Bionics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Paratek Pharmaceuticals00603.00
Ekso Bionics00303.00

Paratek Pharmaceuticals presently has a consensus price target of $18.50, suggesting a potential upside of 259.22%. Ekso Bionics has a consensus price target of $11.00, suggesting a potential upside of 49.66%. Given Paratek Pharmaceuticals' higher probable upside, research analysts plainly believe Paratek Pharmaceuticals is more favorable than Ekso Bionics.

Summary

Paratek Pharmaceuticals beats Ekso Bionics on 8 of the 13 factors compared between the two stocks.

Invacare (NYSE:IVC) and Ekso Bionics (NASDAQ:EKSO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Valuation & Earnings

This table compares Invacare and Ekso Bionics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invacare$927.96 million0.24$-53,330,000.00($1.06)-6.08
Ekso Bionics$13.92 million4.01$-12,130,000.00($3.45)-2.13

Ekso Bionics has lower revenue, but higher earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Ekso Bionics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Invacare has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Ekso Bionics has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500.

Profitability

This table compares Invacare and Ekso Bionics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invacare-4.19%-10.17%-3.73%
Ekso Bionics-68.97%-210.43%-59.23%

Insider and Institutional Ownership

23.5% of Ekso Bionics shares are held by institutional investors. 3.2% of Invacare shares are held by insiders. Comparatively, 24.3% of Ekso Bionics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Invacare and Ekso Bionics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invacare00203.00
Ekso Bionics00303.00

Invacare currently has a consensus target price of $14.00, suggesting a potential upside of 117.05%. Ekso Bionics has a consensus target price of $11.00, suggesting a potential upside of 49.66%. Given Invacare's higher possible upside, equities analysts plainly believe Invacare is more favorable than Ekso Bionics.

Summary

Ekso Bionics beats Invacare on 7 of the 13 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Ekso Bionics (NASDAQ:EKSO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares Fortress Biotech and Ekso Bionics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fortress Biotech-124.73%-58.31%-20.17%
Ekso Bionics-68.97%-210.43%-59.23%

Insider & Institutional Ownership

15.8% of Fortress Biotech shares are held by institutional investors. Comparatively, 23.5% of Ekso Bionics shares are held by institutional investors. 33.1% of Fortress Biotech shares are held by company insiders. Comparatively, 24.3% of Ekso Bionics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Fortress Biotech has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500. Comparatively, Ekso Bionics has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Fortress Biotech and Ekso Bionics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fortress Biotech00403.00
Ekso Bionics00303.00

Fortress Biotech presently has a consensus price target of $10.50, suggesting a potential upside of 290.33%. Ekso Bionics has a consensus price target of $11.00, suggesting a potential upside of 49.66%. Given Fortress Biotech's higher possible upside, equities research analysts plainly believe Fortress Biotech is more favorable than Ekso Bionics.

Earnings and Valuation

This table compares Fortress Biotech and Ekso Bionics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$36.63 million6.06$-39,960,000.00($0.73)-3.68
Ekso Bionics$13.92 million4.01$-12,130,000.00($3.45)-2.13

Ekso Bionics has lower revenue, but higher earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Ekso Bionics, indicating that it is currently the more affordable of the two stocks.

Summary

Fortress Biotech beats Ekso Bionics on 10 of the 13 factors compared between the two stocks.

Jounce Therapeutics (NASDAQ:JNCE) and Ekso Bionics (NASDAQ:EKSO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Earnings and Valuation

This table compares Jounce Therapeutics and Ekso Bionics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jounce Therapeutics$147.87 million1.50$56.82 million$1.663.92
Ekso Bionics$13.92 million4.01$-12,130,000.00($3.45)-2.13

Jounce Therapeutics has higher revenue and earnings than Ekso Bionics. Ekso Bionics is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Jounce Therapeutics and Ekso Bionics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jounce Therapeutics11112.50
Ekso Bionics00303.00

Jounce Therapeutics currently has a consensus target price of $9.50, suggesting a potential upside of 45.93%. Ekso Bionics has a consensus target price of $11.00, suggesting a potential upside of 49.66%. Given Ekso Bionics' stronger consensus rating and higher possible upside, analysts plainly believe Ekso Bionics is more favorable than Jounce Therapeutics.

Volatility and Risk

Jounce Therapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Ekso Bionics has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500.

Insider and Institutional Ownership

75.8% of Jounce Therapeutics shares are owned by institutional investors. Comparatively, 23.5% of Ekso Bionics shares are owned by institutional investors. 44.0% of Jounce Therapeutics shares are owned by company insiders. Comparatively, 24.3% of Ekso Bionics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Jounce Therapeutics and Ekso Bionics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jounce TherapeuticsN/A28.10%21.33%
Ekso Bionics-68.97%-210.43%-59.23%

Summary

Jounce Therapeutics beats Ekso Bionics on 11 of the 15 factors compared between the two stocks.

Ekso Bionics (NASDAQ:EKSO) and Liquidia Technologies (NASDAQ:LQDA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Insider and Institutional Ownership

23.5% of Ekso Bionics shares are owned by institutional investors. Comparatively, 44.9% of Liquidia Technologies shares are owned by institutional investors. 24.3% of Ekso Bionics shares are owned by insiders. Comparatively, 4.3% of Liquidia Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Ekso Bionics and Liquidia Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ekso Bionics-68.97%-210.43%-59.23%
Liquidia TechnologiesN/A-179.43%-81.50%

Valuation & Earnings

This table compares Ekso Bionics and Liquidia Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ekso Bionics$13.92 million4.01$-12,130,000.00($3.45)-2.13
Liquidia Technologies$8.07 million27.39$-47,580,000.00($2.59)-3.01

Ekso Bionics has higher revenue and earnings than Liquidia Technologies. Liquidia Technologies is trading at a lower price-to-earnings ratio than Ekso Bionics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ekso Bionics has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, Liquidia Technologies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Ekso Bionics and Liquidia Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ekso Bionics00303.00
Liquidia Technologies00303.00

Ekso Bionics presently has a consensus price target of $11.00, suggesting a potential upside of 49.66%. Liquidia Technologies has a consensus price target of $37.00, suggesting a potential upside of 374.97%. Given Liquidia Technologies' higher possible upside, analysts clearly believe Liquidia Technologies is more favorable than Ekso Bionics.

Summary

Liquidia Technologies beats Ekso Bionics on 7 of the 12 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
2.0$8.92+2.0%$222.20 million$50,000.000.00Upcoming Earnings
Analyst Downgrade
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$5.15+0.8%$222.12 million$16.54 million-1.48Analyst Downgrade
Invacare logo
IVC
Invacare
1.4$6.45+0.3%$222.04 million$927.96 million-5.56
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$2.69+1.1%$221.86 million$36.63 million-2.92Analyst Revision
Heavy News Reporting
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
2.0$6.51+2.6%$221.69 million$147.87 million5.29
Liquidia Technologies logo
LQDA
Liquidia Technologies
2.1$7.79+6.3%$221.02 million$8.07 million-3.42Insider Buying
High Trading Volume
XOMA logo
XOMA
XOMA
1.5$20.03+4.1%$220.63 million$18.37 million-16.02Analyst Downgrade
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.6$2.54+5.1%$220.30 millionN/A-2.35Analyst Report
Analyst Revision
Heavy News Reporting
RTI Surgical logo
RTIX
RTI Surgical
1.5$2.94+5.1%$219.33 million$308.38 million-0.97Earnings Announcement
Analyst Revision
Heavy News Reporting
Pulse Biosciences logo
PLSE
Pulse Biosciences
2.2$10.50+2.7%$219.12 millionN/A-4.47
American Renal Associates logo
ARA
American Renal Associates
1.3$6.41+1.4%$216.27 million$822.52 million24.65
XCUR
Exicure
0.6$2.48+3.2%$216.13 millionN/A0.00
TLC
TAIWAN LIPOSOME/S
1.2$5.80+0.9%$215.16 million$6.99 million-8.17
OCX
OncoCyte
0.4$1.55+8.4%$215.10 millionN/A0.00Analyst Downgrade
High Trading Volume
Heavy News Reporting
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
2.0$8.22+1.6%$208.43 millionN/A-11.74Analyst Downgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.7$1.94+3.6%$207.52 million$322.07 million3.13Analyst Upgrade
Heavy News Reporting
Joint logo
JYNT
Joint
1.8$14.83+1.1%$206.77 million$48.45 million67.41
DMTK
DermTech
1.5$13.87+3.3%$206.76 million$3.36 million0.00
GNFT
GENFIT S A/ADR
1.5$5.44+1.5%$205.81 million$45.88 million-2.76
Mallinckrodt logo
MNK
Mallinckrodt
1.8$2.43+2.9%$205.23 million$3.16 billion-0.17Analyst Upgrade
Sientra logo
SIEN
Sientra
1.5$4.09+2.7%$204.63 million$83.70 million-1.56
LFVN
LifeVantage
0.9$14.14+4.0%$202.39 million$225.96 million17.90
Aduro BioTech logo
ADRO
Aduro BioTech
1.5$2.50+0.0%$202.09 million$17.26 million-3.05Analyst Downgrade
Heavy News Reporting
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.9$5.25+0.6%$200.43 millionN/A-3.02
NBSE
NeuBase Therapeutics
1.9$8.66+0.2%$200.22 millionN/A0.00
Strongbridge Biopharma logo
SBBP
Strongbridge Biopharma
1.5$3.69+4.6%$200.18 million$21.71 million-3.62Heavy News Reporting
Accuray logo
ARAY
Accuray
1.5$2.17+1.8%$196.43 million$418.79 million108.55
XpresSpa Group logo
XSPA
XpresSpa Group
0.5$4.02+2.2%$196.41 million$48.51 million0.00
Chimerix logo
CMRX
Chimerix
1.5$3.16+0.9%$195.70 million$12.52 million-1.72
LOGC
LogicBio Therapeutics
1.5$8.32+5.4%$194.97 millionN/A-4.52
BSGM
BioSig Technologies
1.8$7.41+3.4%$193.47 millionN/A0.00
Chiasma logo
CHMA
Chiasma
1.5$4.51+3.1%$190.62 millionN/A-4.10Analyst Revision
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.6$10.18+6.6%$189.23 million$1.74 million-5.39Analyst Downgrade
Ritter Pharmaceuticals logo
RTTR
Ritter Pharmaceuticals
0.5$4.10+11.5%$189.23 millionN/A-6.41
ARAV
Aravive
1.6$11.64+1.8%$186.19 million$4.75 million-6.19Analyst Downgrade
Analyst Revision
APYX
Apyx Medical
2.0$5.42+2.2%$185.28 million$28.15 million-11.29
Evolus logo
EOLS
Evolus
1.7$5.48+1.5%$184.83 million$34.92 million-1.61
IMUX
Immunic
1.3$12.30+4.6%$184.11 millionN/A-3.33
AXLA
Axcella Health
2.0$5.29+3.6%$180.85 millionN/A-1.75
GRTX
Galera Therapeutics
1.4$7.21+0.1%$178.99 millionN/A-0.44Analyst Downgrade
Surface Oncology logo
SURF
Surface Oncology
1.3$6.30+3.7%$178.43 million$15.36 million-5.83Analyst Downgrade
NATR
Nature's Sunshine Products
0.8$9.10+1.1%$177.20 million$362.21 million22.20Analyst Downgrade
Sol Gel Technologies logo
SLGL
Sol Gel Technologies
1.3$8.69+0.5%$177.19 million$22.90 million-6.79Analyst Report
Heavy News Reporting
NuCana logo
NCNA
NuCana
1.4$5.39+0.4%$174.98 millionN/A-6.82Heavy News Reporting
Avenue Therapeutics logo
ATXI
Avenue Therapeutics
0.9$10.47+0.3%$174.67 millionN/A-10.79
Sutro Biopharma logo
STRO
Sutro Biopharma
2.1$7.44+4.4%$172.82 million$42.74 million-2.82Heavy News Reporting
T2 Biosystems logo
TTOO
T2 Biosystems
1.3$1.40+8.6%$167.35 million$8.34 million-1.19Unusual Options Activity
TLSA
Tiziana Life Sciences
1.1$6.51+2.9%$167.23 millionN/A-93.00
Galectin Therapeutics logo
GALT
Galectin Therapeutics
1.4$2.92+6.5%$166.52 millionN/A-10.07
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.6$6.43+9.3%$165.67 million$41.69 million-2.94Analyst Downgrade
Analyst Revision
This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.